Skip to Content

Cancer-fighting drug that could help later-stage COVID-19 patients tested at Colorado Springs hospital

Screen Shot 2020-06-07 at 10.55.25 AM

COLORADO SPRINGS, Colo. (KRDO) -- New findings of a cancer-fighting drug, called AstraZeneca's Calquence, is potentially showing a benefit for COVID-19 patients.

Dr. Andrew Monticelli, co-author of the manuscript and medical oncologist with Rocky Mountain Cancer Centers at Penrose Hospital, and Dr. Michael Roshon, Chief of Medical Staff for Penrose-St. Francis, helped pioneer the use of this cancer drug, known for its anti-inflammatory properties.

The use of the drug for coronavirus patients is a collaboration between Centura-Penrose-St. Francis Health Services, the U.S. Oncology Network, AstraZeneca and the National Institutes of Health. 

Dr. Monticelli says, "One interesting thing that kept us excited us is that a lot of patients on ventilators got better, and if you go on a ventilator the death rate is extremely high."

AstraZeneca is launching clinical trails of Calquence involving 200 hospitalized COVID-19 patients. The goal of the trial is to evaluate the efficacy and safety of adding Calquence in patients with life-threatening COVID-19 cases.

Health / Local News / News
Author Profile Photo

Kerjan Bianca

Kerjan is the weekend morning anchor and reporter for KRDO. Learn more about Kerjan here


1 Comment

  1. “New findings of a cancer-fighting drug, called AstraZeneca’s Calquence, is potentially showing a benefit for COVID-19 patients.”
    Let’s hope President Trump doesn’t find out, or he’ll want to start taking it, and people will start hoarding it, making it difficult for cancer patients to really need it to find it.

Comments are closed.